Advanced Chemical Industries Limited

3rd Quarter ended Report 2021-2022 for the nine months period ended on 31 March 2022

Advanced Chemical Industries Limited Statement of financial position Unaudited

			Fig	gures in '000' Taka
			As at	As at
		Note	31 March 2022	30 June 2021
Assets				
Property, plant and equipment		2	13,139,649	12,960,524
Right-of-use assets			395,043	506,003
Investments		3	3,073,712	3,139,924
Intangible assets			2,159	2,807
Biological assets			30,144	17,778
Deferred tax assets			198,186	88,781
Non-current assets	7.00		16,838,894	16,715,817
Inventories		4	6,903,311	6,773,320
Trade receivables		5	2,878,697	2,910,514
Other receivables			687,707	543,149
Inter-company receivables		6	25,155,490	20,142,239
Advances, deposits and prepayments		7	939,793	847,271
Cash and cash equivalents			1,039,756	1,672,220
Current assets			37,604,753	32,888,713
Total assets			54,443,647	49,604,530
Equity				
Share capital			725,768	631,103
Share premium			402,310	402,310
Reserves			5,104,221	5,165,968
Retained earnings			14,033,715	12,693,655
Total equity			20,266,015	18,893,035
Liabilities				
Employee benefits		8	1,352,170	1,123,745
Long term borrowings		9	1,141,514	1,044,720
Non-current portion of lease liabilities			305,771	378,647
Non-current liabilities			2,799,455	2,547,112
Bank overdraft			4,026,709	1,681,373
Loans and borrowings		10	19,306,711	17,068,609
Current portion of lease liabilities			122,258	175,644
Trade payables			1,001,833	1,371,347
Inter-company payables		11	2,952,477	4,269,065
Other payables		12	3,187,154	3,071,296
Unclaimed/unpaid dividend account			93,914	118,208
Current tax liabilities			687,120	408,838
Current liabilities			31,378,177	28,164,381
Total liabilities			34,177,632	30,711,494
Total equity and liabilities	-		54,443,647	49,604,530

Net asset value (NAV) per share (in Taka)

279.24

260.32

Managing Director

Director

Chief Financial Officer

Company Secretary

Advanced Chemical Industries Limited Statement of profit or loss Unaudited

				Figu	res in '000' Taka		
		For the nine m	onths from	For the 3rd Quarter from			
	Note	July 2021 to March 2022	July 2020 to March 2021	January 2022 to March 2022	January 2021 to March 2021		
Revenue	12	40.000					
	13	21,726,378	19,556,207	6,898,031	5,961,991		
Cost of sales	14	(12,339,323)	(10,818,769)	(4,033,635)	(3,324,771)		
Gross profit		9,387,056	8,737,438	2,864,397	2,637,220		
Administrative, selling and distribution expenses	15	(7,030,294)	(6,289,605)	(2,209,763)	(1,878,374)		
Other income		496,103	476,197	29,992	11,662		
Operating profit		2,852,865	2,924,029	684,626	770,508		
Net finance costs		(263,152)	(225,773)	(60,604)	(45,315)		
Profit before contribution to WPPF		2,589,714	2,698,256	624,022	725,192		
Contribution to WPPF		(129,486)	(134,913)	(31,201)	(36,260)		
Profit before tax		2,460,228	2,563,343	592,821	688,933		
Income tax expense		(615,285)	(676,757)	(137,892)	(189,975)		
Profit after tax		1,844,943	1,886,586	454,929	498,958		
Earnings per share							
Basic and diluted earnings per share (EPS) (in Taka)		25.42	25.99	6.27	6.87		

Managing Director

Director

Chief Financial Officer

//Company Secretary

Advanced Chemical Industries Limited Statement of profit or loss and other comprehensive income Unaudited

	For the nine	months from	Figur For the 3rd Q	es in '000' Taka uarter from
Other comprehensive income:	July 2021 to March 2022	July 2020 to March 2021	January 2022 to March 2022	January 2021 to March 2021
Profit after tax	1,844,943	1,886,586	454,929	498,958
Other comprehensive income:				
Change in fair value of FVOCI financial assets	(68,607)	25,563	(17,152)	-
Income tax on FVOCI financial assets	6,861	(2,556)	1,715	-
Other comprehensive income, net of tax	(61,746)	23,007	(15,437)	-
Total comprehensive income	1,783,196	1,909,593	439,492	498,958

Advanced Chemical Industries Limited Statement of changes in equity Unaudited

						Figures in	n '000' Taka
				For th	e nine months fr	om July 2021 to	March 2022
	Share capital	Share premium	Capital reserve	FVOCI reserve	Revaluation surplus	Retained earnings	Total equity
Balance at 1 July 2021	631,103	402,310	1,671	453,052	4,711,245	12,693,655	18,893,035
Total comprehensive income							
Profit after tax	-	-	-	-	-	1,844,943	1,844,943
Other comprehensive income-net of tax	-	-	-	(61,746)	-	-	(61,746)
Total comprehensive income	-	-	-	(61,746)	-	1,844,943	1,783,196
Transaction with owners of the Company							
Share premium	-	-	-	-	-	-	-
Stock dividend	94,665	-	-	-	-	(94,665)	-
Cash dividend	-	-	-	-	-	(410,217)	(410,217)
Total transactions with owners of the Company	94,665	-	-	-	-	(504,882)	(410,217)
Balance at 31 March 2022	725,768	402,310	1,671	391,305	4,711,245	14,033,715	20,266,015

				For th	ne nine months fr	om July 2020 to	March 2021
	Share capital	Share premium	Capital reserve	FVOCI reserve	Revaluation surplus	Retained earnings	Total equity
Balance at 1 July 2020	573,730	402,310	1,671	434,656	3,075,541	10,933,326	15,421,234
Total comprehensive income							
Profit after tax	-	-	-	-	-	1,886,586	1,886,586
Other comprehensive income-net of tax	-	-	-	23,007	-	-	23,007
Total comprehensive income	-	-	-	23,007	-	1,886,586	1,909,593
Transaction with owners of the Company							
Share premium	-	-	-	-	-	-	_
Stock dividend	57,373	-	-	-	-	(57,373)	_
Cash dividend		-	-	-		(458,984)	(458,984)
Total transactions with owners of the Company	57,373	-	-	-	-	(516,357)	(458,984)
Balance at 31 March 2021	631,103	402,310	1,671	457,663	3,075,541	12,303,555	16,871,844

Advanced Chemical Industries Limited Statement of cash flows Unaudited

		gures in '000' Taka
	For the nine	months from
	July 2021	July 2020
	to	to
	March 2022	March 2021
Cash flows from operating activities		
Cash receipts from customers and others	21,607,726	19,521,247
Cash paid to suppliers and employees	(19,078,381)	(17,291,835)
Cash generated from operating activities	2,529,345	2,229,412
Paid to WPPF	(129,888)	(88,560)
Finance costs paid	(254,398)	(190,664)
Income tax paid	(439,548)	(620,197)
The state of the s	(823,834)	(899,421)
Net cash from / (used in) operating activities* 16	1,705,511	1,329,991
Cook flows from investing estivities		
Cash flows from investing activities Acquisition of property, plant and equipment	(135,058)	(170,337)
Payments for capital work in progress	(409,696)	(548,485)
	4,190	4,346
Sale proceeds from property, plant and equipment	•	•
Purchase of biological assets Dividend received	(13,157) 425,037	(6,548)
Investment	(2,395)	442,728 (90,000)
Net cash from / (used in) investing activities	(131,079)	(368,297)
Cash flows from financing activities		
Inter-company debts received/(paid)	(6,329,839)	(5,520,089)
Dividend paid	(434,511)	(471,180)
Payment for lease liabilities	(131,028)	(119,281)
Short-term bank loan received/(paid)	2,201,942	4,110,967
Long-term bank loan received/(paid)	132,954	274,461
Net cash from / (used in) financing activities	(4,560,482)	(1,725,122)
Net increase / (decrease) in cash and cash equivalents	(2,986,049)	(763,427)
Opening cash and cash equivalents	(9,153)	(1,715,137)
Effect of movements in exchange rates on cash held	8,249	-
Closing cash and cash equivalents	(2,986,953)	(2,478,564)
Closing balance represents		
Cash and cash equivalents	1,039,756	791,721
Bank overdraft	(4,026,709)	(3,270,285)
	(., = 20, , =)	
	(2,986,953)	(2,478,564)

^{*}See Note 16 for reconciliation of net operating cash flow.

Advanced Chemical Industries Limited Consolidated statement of financial position Unaudited

	Unaudited	TO:	gures in '000' Taka
		As at	As at
	Note	31 March 2022	30 June 2021
Assets			
Property, plant and equipment	2 (a)	29,855,781	29,821,715
Right-of-use assets	2 (a)	1,442,509	1,497,953
Equity-accounted investees		1,879,637	1,927,913
Other investments		759,441	810,600
Intangible assets		87,129	93,940
Biological assets		30,144	17,77
Deferred tax assets		729,808	448,00
Non-current assets		34,784,451	34,617,909
Inventories	4 (a)	19,471,635	17,349,949
Trade receivables	5 (a)	13,477,263	12,015,538
Other receivables		1,050,459	815,433
Inter-company receivables	6 (a)	9,799	9,586
Advances, deposits and prepayments	7 (a)	2,367,572	2,300,942
Short term investments		.=.	1,158,369
Cash and cash equivalents		2,083,696	3,831,929
Current assets		38,460,424	37,481,74
Total assets		73,244,875	72,099,65
Equity			
Share capital		725,768	631,103
Share premium		1,182,924	928,70
Reserves		6,978,533	7,084,649
Retained earnings		1,318,097	1,620,38
Equity attributable to the owners of the Company	F	10,205,321	10,264,84
Non-controlling interest			
Total equity		1,892,545 12,097,866	838,20° 11,103,05°
		12,097,800	11,103,05
Liabilities Employee benefits	8 (a)	1,763,470	1,462,87
Long term borrowings	9 (a)	7,034,663	7,843,74
Non-current portion of lease liabilities	<i>y</i> (u)	1,143,282	1,161,243
Non-current liabilities		9,941,415	10,467,869
Bank overdraft		5,810,845	3,543,94
Loans and borrowings	10 (a)	33,054,802	34,516,42
Current portion of lease liabilities	10 (a)	380,550	434,02
Trade payables		4,693,151	4,540,65
Other payables	12 (a)	6,787,108	7,303,909
Unclaimed/unpaid dividend account	12 (a)	99,282	131,17
Current tax liabilities		379,857	58,60
Current liabilities		51,205,594	50,528,739
Total liabilities		61,147,009	60,996,604
Total equity and liabilities		73,244,875	72,099,655
Net asset value (NAV) per share (in Taka)	18	140.61	141.43

Managing Director

amon S. Salman

Chief Financial Officer

Company Secretary

Advanced Chemical Industries Limited Consolidated statement of profit or loss Unaudited

				Figu	es in '000' Taka
		For the nine	months from	For the 3rd Q	uarter from
	Note	July 2021 to March 2022	July 2020 to March 2021	January 2022 to March 2022	January 2021 to March 2021
-					
Revenue	13 (a)	69,362,622	56,969,655	23,543,973	19,591,325
Cost of sales	14 (a)	(50,803,599)	(41,150,999)	(17,592,246)	(14,471,945)
Gross profit		18,559,023	15,818,656	5,951,727	5,119,380
Administrative, selling and distribution expenses	15 (a)	(13,885,225)	(12,068,984)	(4,605,870)	(3,886,251)
Other income / (loss)		235,162	269,167	78,003	78,809
Operating profit		4,908,961	4,018,840	1,423,860	1,311,938
Share of the profit of equity accounted investees		299,313	360,063	84,964	108,399
Net finance costs		(2,765,238)	(2,653,064)	(932,765)	(859,410)
Profit before contribution to WPPF		2,443,036	1,725,839	576,059	560,927
Contribution to WPPF		(254,989)	(216,979)	(70,274)	(63,144)
Profit before tax		2,188,047	1,508,860	505,785	497,783
Income tax expense		(1,439,759)	(1,347,627)	(367,270)	(496,550)
Profit after tax		748,287	161,233	138,516	1,233
Profit attributable to:				350	
Equity holders of the company		431,932	223,146	31.697	21.007
Non-controlling interests		316,355	(61,913)	106,819	21,887
Profit after tax		748,287	161,233	138,516	(20,654) 1,233
			· · · · · · · · · · · · · · · · · · ·	, , , , , , , , , , , , , , , , , , , ,	-,200
Earnings per share	10		E		
Basic and diluted earnings per share (EPS) (in Taka)	18	5.95	3.07	0.44	0.30

Managing Director

Director

Chief Financial Officer

Company Secretary

Advanced Chemical Industries Limited Consolidated statement of profit or loss and other comprehensive income Unaudited

	For the nine m	onths from	Figur For the 3rd Q	res in '000' Taka Juarter from
	July 2021 to March 2022	July 2020 to March 2021	January 2022 to March 2022	January 2021 to March 2021
Profit after tax	748,287	161,233	138,516	1,233
Other comprehensive income:				
Foreign operations - foreign currency translation differences	(42,300)	-	(19,266)	233
Change in fair value of FVOCI financial assets	(69,869)	25,806	(18,121)	(272)
Income tax on other comprehensive income	6,987	(2,581)	1,812	27
Other comprehensive income, net of tax	(105,183)	23,225	(35,575)	(11)
Total comprehensive income	643,105	184,458	102,940	1,221
Total comprehensive income attributable to:				
Equity holders of the Company				
Profit after tax	431,932	223,146	31,697	21,887
Other comprehensive income	(101,586)	23,198	(33,751)	(21)
	330,347	246,344	(2,054)	21,865
Non-controlling interest				
Profit after tax	316,355	(61,913)	106,819	(20,654)
Other comprehensive income	(3,597)	27	(1,825)	10
	312,758	(61,886)	104,994	(20,644)
Total comprehensive income	643,105	184,458	102,940	1,221

Advanced Chemical Industries Limited Consolidated Statement of changes in equity Unaudited

Figure	s in	'000'	l'aka
For the nine months from July 2021	to N	Iarch	2022

			A	ttributable to o	wners of the (Company				
	Share capital	Share premium	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total	Non-controlling Interests	Total equity
Balance at 1 July 2021	631,103	928,707	1,671	(1,397)	452,007	6,632,367	1,620,385	10,264,844	838,207	11,103,051
Total comprehensive income										
Profit after tax	-	-	-	-	-	-	431,932	431,932	316,355	748,287
Other comprehensive income-net of tax	-		-	(39,313)	(62,273)	-	-	(101,586)	(3,597)	(105,183)
Total comprehensive income	-	-	-	(39,313)	(62,273)	-	431,932	330,347	312,758	643,105
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend	94,665	-	-	-	-	-	(94,665)	-	-	-
Cash dividend	-	-	-	-	-	-	(410,217)	(410,217)	(62,802)	(473,018)
Effect of issuing new shares to Bangladesh Managed Account C.V. (a										
limited partnership of FMO) by ACI Motors Ltd.	-	254,217	-	-	10	(4,540)	(229,338)	20,348	648,826	669,173
Capital contribution by non-controlling interest (BMA C.V.)	-	-	-	-	-	-	-	-	155,556	155,556
Total transactions with owners of the Company	94,665	254,217	-	-	10	(4,540)	(734,220)	(389,869)	741,579	351,711
Balance at 31 March 2022	725,768	1,182,924	1,671	(40,710)	389,744	6,627,827	1,318,097	10,205,321	1,892,545	12,097,866

For the nine months from July 2020 to March 2021

			A	ttributable to o	wners of the	Company			•	
	Share capital	Share premium	Capital reserve	Translation reserve	FVOCI reserve	Revaluation surplus	Retained earnings	Total	Non-controlling Interests	Total equity
Balance at 1 July 2020	573,730	402,310	1,671	(1,397)	433,047	4,277,934	2,211,343	7,898,638	(608,661)	7,289,977
Total comprehensive income										
Profit after tax	-	-	-	-	-	-	223,146	223,146	(61,913)	161,233
Other comprehensive income-net of tax	-		-	-	23,197	-	-	23,197	28	23,225
Total comprehensive income	-	-	-	-	23,197	_	223,146	246,343	(61,885)	184,458
Transaction with owners of the Company										
Share premium	-	-	-	-	-	-	-	-	-	-
Stock dividend	57,373	-	-	-	-	-	(57,373)	-	-	-
Cash dividend	-	-	-	-	-	-	(458,984)	(458,984)	(41,868)	(500,851)
Effect of issuing new shares to Bangladesh Managed Account C.V. (a limited partnership of FMO) by ACI Motors Ltd.	-	526,397	-	-	-	-	(298,367)	228,030	770,774	998,805
Capital contribution by non-controlling interest (BMA C.V.)	-	-	-	-	-	-	-	-	233,333	233,333
Total transactions with owners of the Company	57,373	526,397	-	-	-	-	(814,723)	(230,953)	962,240	731,287
Balance at 31 March 2021	631,103	928,707	1,671	(1,397)	456,244	4,277,934	1,619,766	7,914,028	291,693	8,205,722

Advanced Chemical Industries Limited Consolidated statement of cash flows Unaudited

Cash flows from operating activities Cash receipts from customers and others Cash paid to suppliers and employees Cash generated from operating activities Paid to WPPF Finance costs paid	For the nine m July 2021 to March 2022 67,795,721 (65,391,921) 2,403,800 (260,620)	nonths from July 2020 to March 2021 56,450,136 (56,595,167) (145,031)
Cash receipts from customers and others Cash paid to suppliers and employees Cash generated from operating activities Paid to WPPF	to March 2022 67,795,721 (65,391,921) 2,403,800 (260,620)	to March 2021 56,450,136 (56,595,167) (145,031)
Cash receipts from customers and others Cash paid to suppliers and employees Cash generated from operating activities Paid to WPPF	March 2022 67,795,721 (65,391,921) 2,403,800 (260,620)	56,450,136 (56,595,167) (145,031)
Cash receipts from customers and others Cash paid to suppliers and employees Cash generated from operating activities Paid to WPPF	67,795,721 (65,391,921) 2,403,800 (260,620)	56,450,136 (56,595,167) (145,031)
Cash receipts from customers and others Cash paid to suppliers and employees Cash generated from operating activities Paid to WPPF	(65,391,921) 2,403,800 (260,620)	(56,595,167) (145,031)
Cash receipts from customers and others Cash paid to suppliers and employees Cash generated from operating activities Paid to WPPF	(65,391,921) 2,403,800 (260,620)	(56,595,167) (145,031)
Cash paid to suppliers and employees Cash generated from operating activities Paid to WPPF	(65,391,921) 2,403,800 (260,620)	(56,595,167) (145,031)
Cash generated from operating activities Paid to WPPF	2,403,800 (260,620)	(145,031)
Paid to WPPF	(260,620)	, , ,
		(151 /122)
Finance costs paid	(2.207.050)	(131,400)
	(2,307,958)	(1,997,965)
Income tax paid	(1,379,831)	(1,541,192)
	(3,948,409)	(3,690,645)
Net cash from / (used in) operating activities * 16 (a)	(1,544,609)	(3,835,675)
Cash flows from investing activities		
Acquisition of property, plant and equipment	(315,022)	(505,661)
Payments for capital work in progress	(888,020)	(761,638)
Sale proceeds from property, plant and equipment	4,850	4,966
Purchase of biological assets	(13,157)	(6,548)
Dividend received	352,839	394,595
Short term investments	1,158,369	(72,940)
Long term investments	(15,393)	(91,876)
Net cash from / (used in) investing activities	284,467	(1,039,102)
Cash flows from financing activities		
Inter-company debts received/(paid)	(212)	(66)
Dividend paid	(434,511)	(471,180)
Payment for lease liabilities	(323,197)	(313,452)
Dividend paid to non-controlling interest	(70,403)	(41,443)
Equity investment received by ACI Motors Limited	824,729	1,232,138
Short-term bank loan received/(paid)	(1,907,407)	7,052,688
Long-term bank loan received/(paid)	(852,191)	(1,855,254)
Net cash from / (used in) financing activities	(2,763,193)	5,603,430
Net increase / (decrease) in cash and cash equivalents	(4,023,335)	728,652
Opening cash and cash equivalents	287,985	(2,627,972)
Effect of movements in exchange rates on cash held	8,201	108
Closing cash and cash equivalents	(3,727,149)	(1,899,212)
Closing balance represents		
Cash and cash equivalents	2,083,696	3,281,944
Bank overdraft	(5,810,845)	(5,181,155)
	(3,727,149)	(1,899,212)
Net operating cash flows per share (NOCFPS) (in Taka) 18	(21.28)	(52.85)

^{*}See Note 16(a) for reconciliation of consolidated net operating cash flow.

Advanced Chemical Industries Limited Notes to the financial statements as at and for the 3rd Quarter ended on 31 March 2022 Unaudited

1 Selected explanatory notes

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended from 1 July 2020 to 30 June 2021. This interim financial report includes only those selected explanatory notes as deemed appropriate for better understanding of unaudited financial statements.

_		9	res III 000 Taka
2	Property, plant and equipment	31 March 2022	30 June 2021
		Taka	Taka
	Opening balance	15,407,109	12,626,796
	Additions and revaluation	544,754	2,840,675
	Disposals and adjustments	(9,073)	(60,362)
	Accumulated depreciation	(2,803,141)	(2,446,585)
	Closing balance	13,139,649	12,960,524
2 (a)	Consolidated property, plant and equipment		
	Opening balance	36,936,223	32,255,436
	Additions and revaluation	1,196,995	4,750,379
	Disposals and adjustments	(26,390)	(65,066)
	Accumulated depreciation	(8,251,046)	(7,119,033)
	Closing balance	29,855,781	29,821,715
3	Investments		
	Investment in subsidiaries	1,751,736	1,751,736
	Investment in joint ventures	510,000	510,000
	Investment in associates	548,794	546,398
	Investment in shares	466,238	534,846
	Investment in FDR/ other deposits	70,544	70,544
	Impairment	(273,600)	(273,600)
		3,073,712	3,139,924
4	Inventories		
	Raw materials	2,594,552	2,461,746
	Packing materials	618,699	687,806
	Work-in-process	345,227	304,842
	Finished goods	3,345,524	3,231,157
	Goods in transit	503,517	447,602
	Stores and spares	100,218	99,111
	Allowance for inventory	(604,426)	(458,945)
		6,903,311	6,773,320

		Fig 31 March 2022 Taka	gures in '000' Taka 30 June 2021 Taka		
4 (a)	Consolidated inventories				
	Raw materials	5,455,623	4,707,203		
	Packing materials	702,674	773,367		
	Work-in-process	682,975	540,242		
	Finished goods	11,369,192	10,092,334		
	Goods in transit	1,890,438	1,703,227		
	Stores & spares	288,674	257,385		
	Allowance for inventory	(917,941)	(723,808)		
		19,471,635	17,349,949		
5	Trade receivables				
	Debts due over six months	1,870,731	2,104,043		
	Debts due below six months	1,886,028	1,492,357		
	Provision for doubtful debts	(878,062)	(685,886)		
		2,878,697	2,910,514		
5 (a)	Consolidated trade receivables				
	Debts due over six months	4,025,707	4,139,826		
	Debts due below six months	11,029,432	9,180,570		
	Provision for doubtful debts	(1,577,876)	(1,304,858)		
		13,477,263	12,015,538		
6	Inter-company receivables				
	ACI Logistics Limited	7,993,056	5,968,826		
	ACI HealthCare Limited	6,573,213	6,131,061		
	Premiaflex Plastics Limited	3,775,139	2,802,198		
	ACI Foods Limited	3,627,976	2,680,268		
	ACI Biotech Limited	940,804	884,172		
	ACI Agrolink Limited	718,734	582,493		
	ACI HealthCare USA Inc.	590,997	-		
	Infolytx Bangladesh Limited	578,073	447,765		
	ACI Chemicals Limited	227,911	211,884		
	ACI Formulations Limited	119,790	346,312		
	Asian Consumer Care (Pvt.) Limited	7,894	7,894		
	Tetley ACI (Bangladesh) Limited	945	580		
	ACI Godrej Agrovet (Pvt.) Limited	930	930		
	Computer Technology Limited	30	30		
	Stochastic Logic Limited	-	152		
	Creative Communication Limited	-	19,352		
	ACI Edible Oils Limited	-	58,323		
		25,155,490	20,142,239		

		Fig 31 March 2022 Taka	Figures in '000' Taka 30 June 2021 Taka	
6 (a)	Consolidated inter-company receivables			
	Computer Technology Limited	30	30	
	Tetley ACI (Bangladesh) Limited	945	580	
	Asian Consumer Care (Pvt.) Limited	7,894	7,894	
	ACI Godrej Agrovet (Pvt.) Limited	930	930	
	Stochastic Logic Limited	-	152	
		9,799	9,586	
7	Advances, deposits & prepayments			
	Advances to staff, suppliers and others	228,951	205,689	
	VAT current account	243,304	361,723	
	Deposits	232,818	239,115	
	Prepayments	234,720	40,743	
		939,793	847,271	
7 (a)	Consolidated advances, deposits & prepayments			
	Advances to staff, suppliers and others	967,496	852,166	
	VAT current account	498,732	767,475	
	Advance for capital expenditure	-	733	
	Deposits	434,560	427,409	
	Prepayments	466,784	253,159	
		2,367,572	2,300,942	
8	Employee benefits			
	Staff gratuity provision	1,106,737	920,330	
	Other long term employee benefits	245,433	203,415	
		1,352,170	1,123,745	
8 (a)	Consolidated employee benefits			
	Staff gratuity provision	1,427,286	1,181,776	
	Other long term employee benefits	336,183	281,099	
		1,763,470	1,462,875	

		31 March 2022 Taka	30 June 2021 Taka
9	Long term borrowings		
	Long term bank loans	1,141,514	1,044,720
		1,141,514	1,044,720
9 (a)	Consolidated long term borrowings		
	Long term bank loans	7,034,663	7,843,747
		7,034,663	7,843,747
10	Loans and borrowings - short term		
	Short term loan	19,096,834	16,894,892
	Current portion of long term loan	209,878	173,718
		19,306,711	17,068,609
10 (a)	Consolidated loans and borrowings - short term		
	Short term loan	30,447,723	32,274,988
	Current portion of long term loan	2,607,079	2,241,433
		33,054,802	34,516,421
11	Inter company payables		
	ACI Marine and Riverine Technologies Limited	29,803	4,472
	ACI Motors Limited	725,958	2,252,705
	ACI Salt Limited	1,734,613	1,434,750
	ACI Pure Flour Limited	368,326	577,138
	ACI Edible Oils Limited	30,248	-
	Creative Communication Limited	59,714	-
	ACI Formulations Limited	-	-
	Stochastic Logic Limited	3,816	-
		2,952,477	4,269,065

		31 March 2022 Taka	30 June 2021 Taka
12	Other payables		
	Accruals	1,716,694	1,581,957
	Advance from customers	2,977	241,778
	Security money received from customers	37,080	49,769
	Workers' profit participation fund	776,943	742,852
	Tax and VAT deducted at source	116,545	88,518
	Employees welfare fund	395,141	292,091
	Rights share deposit to be refunded	564	564
	Family day fund	5,776	5,492
	Non-management staff provident fund	6,153	6,107
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
	Payable for redemption of Zero Coupon Bonds	20,403	20,403
	Management staff provident fund	14,265	8,930
	Advertisement and promotional funds	79,831	16,747
	Development funds	11,134	12,440
•	•	3,187,154	3,071,296
10 ()			
12 (a)	Consolidated other payables		
	Accruals	4,368,637	4,443,912
	Advance from customers	435,140	1,186,756
	Security money received from customers	94,395	103,129
	Workers' profit participation fund	1,046,087	1,006,003
	Management staff provident fund	14,265	8,930
	Tax and VAT deducted at source	281,856	172,566
	Employees welfare fund	412,519	312,659
	Rights share deposit to be refunded	564	564
	Family day fund	5,776	5,492
	Non-management staff provident fund	6,153	6,107
	Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
	Payable for redemption of Zero Coupon Bonds	20,403	20,403
	Creditors for capital expenditure	6,701	4,553
	Advertisement and promotional funds	79,831	16,747
	Development funds	11,134	12,440
		6,787,108	7,303,909

		For the nine n	ires in 000 Taka	
		July 2021	July 2020	
		to	to	
		March 2022	March 2021	
10	D	<u> </u>	Taka	
13	Revenue			
	Pharmaceuticals	10,760,228	9,036,782	
	Animal health	3,378,825	3,259,198	
	Consumer brands	5,212,007	5,432,817	
	Seeds	886,334	913,954	
	Fertilizer	1,296,288	797,062	
	Animal genetics	192,696	116,394	
•	rimmar genetics	21,726,378	19,556,207	
1				
13 (a)	Consolidated revenue			
	Gross sales	70,904,862	58,247,650	
	Inter-company sales	(1,542,240)	(1,277,995)	
•		69,362,622	56,969,655	
•			_	
14	Cost of sales			
	Opening stock	6,685,551	4,817,762	
	Purchase	10,794,838	10,897,004	
•		17,480,389	15,714,766	
	Closing stock	(6,904,002)	(6,590,687)	
•		10,576,387	9,124,080	
	Manufacturing expenses	1,762,936	1,694,690	
		12,339,323	10,818,769	
147				
14 (a)	Consolidated cost of sales			
	Opening stock	16,031,441	11,902,574	
_	Purchase	49,812,847	42,902,395	
		65,844,288	54,804,969	
	Closing stock	(18,214,010)	(16,585,584)	
•		47,630,278	38,219,384	
	Manufacturing expenses	3,173,321	2,931,614	
	<u> </u>	50,803,599	41,150,999	
15	A durinistration calling and distribution arrange			
15	Administrative, selling and distribution expenses			
	Administrative expenses	451,606	289,164	
	Distribution expenses	869,831	745,390	
	Selling expenses	5,708,856	5,255,051	
•		7,030,294	6,289,605	

		For the nine n	nonths from
		July 2021	July 2020
		to	to
		March 2022	March 2021
		Taka	Taka
15 (a)	Consolidated operating expenses		
	Administrative expenses	2,292,205	2,128,583
	Distribution expenses	1,895,861	1,480,350
	Selling expenses	9,697,159	8,460,052
-		13,885,225	12,068,984
16	Reconciliation of net operating cash flow		
	Profit after tax	1,844,943	1,886,586
	Adjustment for non-cash items and others:		
	- Depreciation and amoritisation	365,769	361,913
	- Provisions	337,657	446,982
	- Finance cost	263,152	225,773
	- Tax Expense	615,285	676,757
	- Contribution to WPPF	129,486	134,912
	-Lease and other adjustments	120,663	117,102
	Changes in:		
	- Inventories	(275,473)	(1,664,625)
	- Trade and other receivables	(729,953)	(385,684)
	- Advances, deposits and prepayments	(74,611)	(100,058)
	- Trade and other payables, employment benefits	(67,572)	529,754
	Cash generated from operating activities	2,529,345	2,229,412
	Paid to WPPF	(129,888)	(88,560)
	Interest paid	(254,398)	(190,664)
	Income tax paid	(439,548)	(620,197)
	Net cash from operating activities	1,705,511	1,329,991
16 (a)	Reconciliation of Consolidated net operating cash flow		
	Profit after tax	748,287	161,233
	Adjustment for non-cash items and others:		
	- Depreciation and amoritisation	1,146,692	1,166,407
	- Provisions	467,151	537,939
	- Share of profit of equity accounted investees	(299,313)	(360,063)
	- Finance cost	2,765,238	2,653,064
	- Tax Expense	1,439,759	1,347,627
	- Contribution to WPPF	254,989	216,979
	-Lease and other adjustments	323,197	278,277

Changes in:		
- Inventories	(2,315,819)	(5,189,820)
- Trade and other receivables	(1,969,769)	(589,664)
- Advances, deposits and prepayments	(82,332)	(644,779)
- Trade and other payables, Employment benefits	(74,281)	277,770
Net cash from operating activities	2,403,800	(145,031)
Paid to WPPF	(260,620)	(151,488)
Interest paid	(2,307,958)	(1,997,965)
Income tax paid	(1,379,831)	(1,541,192)
Net cash from operating activities	(1,544,609)	(3,835,675)

17 Consolidated operating segments Please see Annexure A.

18

For the nine months from			
July 2021	July 2020		
to	to		
March 2022	March 2021		
72,577	72,577		
	223,146		
5.95	3.07		
(1,544,609)	(3,835,675)		
(21.28)	(52.85)		
31 March 2022	30 June 2021		
Taka	Taka		
10,205,321	10,264,844		
140.61	141.43		
	July 2021 to March 2022 72,577 431,932 5.95 (1,544,609) (21.28) 31 March 2022 Taka 10,205,321		

Reasons for significant deviations: During the nine months period ended on 31 March 2022, the Group achieved a significant revenue growth which was mainly contributed by the sales growth in some of the business segments as demonstrated in Annexure-A: Consolidated operating segments. The higher growth in consolidated revenue compared to the growth in expenses contributed to the increase in consolidated profit compared to the SPLY. The consequential results of increased consolidated revenue and profit ultimately contributed to improve consolidated EPS and NOCFPS.

Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.

Annexure-A
Consolidated operating segments

Figures in '000' Taka For the nine months from July 2021 to March 2022

	Reportable Segment										Total	Unallocated/		
Particulars	Pharmaceuticals	Animal	Consumer	Crop Care and	Motors	Pure Flour	Retail Chain	Salt	Foods	Premiaflex	HealthCare	reportable	Elimination	Total
	Tharmaceuticais	Health	Brands	Public Health	Motors	Ture Piour	Retail Chain	Sait	Toous	Tiennanex	TieattiiCare	segments	Emimation	
External revenue	10,760,228	3,378,825	4,999,035	2,751,930	14,994,190	4,374,156	9,910,500	2,234,941	5,639,890	4,651,167	1,262,543	64,957,408	4,405,215	69,362,622
Inter-segment revenue	-	-	601,237	-	35,964	79,012	55,228	33,131	122,502	437,134	-	1,364,207	178,032	1,542,240
Segment revenue	10,760,228	3,378,825	5,600,271	2,751,930	15,030,154	4,453,168	9,965,728	2,268,072	5,762,392	5,088,302	1,262,543	66,321,615	4,583,247	70,904,862
Depreciation and amortisation	227,416	21,021	73,649	13,252	55,877	28,887	111,453	54,480	48,830	200,638	263,695	1,099,198	47,494	1,146,692
Operating expenses	4,597,622	680,940	1,435,854	470,458	1,990,778	202,722	1,847,577	222,676	483,851	410,294	873,023	13,215,796	669,429	13,885,225
Finance cost / (income)	114,820	73,440	76,079	80,612	227,647	(30,642)	933,696	(67,064)	215,197	356,244	682,141	2,662,171	103,066	2,765,238
Segment profit/(loss) before tax	1,836,599	172,818	(280,548)	397,954	1,524,985	20,353	(903,579)	414,607	77,215	(101,776)	(1,363,170)	1,795,458	392,589	2,188,047
Segment assets at 31 Mar 2022	11,833,825	2,061,532	4,904,599	2,685,296	13,230,530	1,826,138	4,022,172	3,175,542	3,202,194	7,255,639	8,405,791	62,603,256	10,641,619	73,244,875
Segment liabilities at 31 Mar 2022	3,923,017	711,978	2,045,591	1,281,208	5,835,262	625,714	18,369,617	1,227,697	4,962,844	6,717,488	13,289,226	58,989,642	2,157,367	61,147,009

For the nine months from July 2020 to March 2021

	Reportable segment											Total	Unallocated/	
Particulars	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Premiaflex	HealthCare	reportable segments	Elimination	Total
External revenue	9,036,782	3,259,198	5,267,126	2,374,723	9,683,525	3,882,235	9,492,648	1,291,863	4,430,988	4,093,964	1,154,778	53,967,830	3,001,825	56,969,655
Inter-segment revenue	-	-	518,504	-	20,794	44,647	37,146	50,586	68,232	383,127	-	1,123,037	154,957	1,277,995
Segment revenue	9,036,782	3,259,198	5,785,630	2,374,723	9,704,319	3,926,882	9,529,794	1,342,450	4,499,220	4,477,091	1,154,778	55,090,868	3,156,782	58,247,650
Depreciation and amortisation	235,644	19,797	58,387	15,149	50,634	26,054	140,549	38,341	48,169	194,813	262,526	1,090,063	76,344	1,166,407
Operating expenses	3,857,088	673,076	1,708,372	420,817	1,225,219	205,461	1,819,109	179,659	386,620	402,046	891,718	11,769,185	299,799	12,068,984
Finance cost / (income)	81,880	80,180	19,740	89,511	202,185	(34,555)	943,092	(53,720)	222,154	344,743	623,389	2,518,600	134,464	2,653,064
Segment profit/(loss) before tax	1,718,871	265,500	(226,366)	322,556	917,494	55,057	(1,016,905)	235,348	23,088	81,569	(1,385,623)	990,591	518,269	1,508,860
														_
Segment assets at 30 June 2021	11,932,171	2,700,827	4,757,239	2,546,825	14,051,260	1,716,688	3,693,664	2,660,555	2,676,007	6,920,779	9,423,781	63,079,796	9,019,860	72,099,655
Segment liabilities at 30 June 2021	3,556,097	1,557,332	1,764,652	1,672,648	8,575,159	511,893	17,077,548	994,856	4,476,547	6,156,294	13,006,408	59,349,435	1,647,169	60,996,604